VRTX
NASDAQ · Biotechnology
Vertex Pharmaceuticals Inc
$494.74
-4.91 (-0.98%)
Financial Highlights (FY 2026)
Revenue
11.54B
Net Income
3.80B
Gross Margin
86.2%
Profit Margin
32.9%
Rev Growth
+10.4%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 86.2% | 86.2% | 56.9% | 56.9% |
| Operating Margin | 34.8% | 31.3% | 11.0% | 10.1% |
| Profit Margin | 32.9% | 31.3% | 8.5% | 11.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.54B | 10.46B | 15.93B | 17.43B |
| Gross Profit | 9.95B | 9.02B | 9.06B | 9.91B |
| Operating Income | 4.01B | 3.27B | 1.76B | 1.76B |
| Net Income | 3.80B | 3.10B | 1.35B | 1.92B |
| Gross Margin | 86.2% | 86.2% | 56.9% | 56.9% |
| Operating Margin | 34.8% | 31.3% | 11.0% | 10.1% |
| Profit Margin | 32.9% | 31.3% | 8.5% | 11.0% |
| Rev Growth | +10.4% | +10.4% | -6.3% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 363.44M | 363.44M | 13.83B | 14.35B |
| Total Equity | 60.57B | 60.57B | 91.42B | 88.18B |
| D/E Ratio | 0.01 | 0.01 | 0.15 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.21B | 3.63B | 2.28B | 2.59B |
| Free Cash Flow | — | — | 1.35B | 2.40B |